Skip to main content

Advertisement

SpringerLink
Log in

Cys–X–Cys ligand 9 might be an immunological factor in the pathogenesis of oral submucous fibrosis and its concomitant oral lichenoid lesion

  • Original Article
  • Published:
Clinical Oral Investigations Aims and scope Submit manuscript

Abstract

Objectives

Oral submucous fibrosis (OSF) is a chronic oral precancerous disease primarily caused by betel quid chewing. Some OSF patients are concomitant with oral lichenoid lesion (OLL), a white-streak lesion with a higher risk for cancerization, in OSF mucosa. Immunological reaction has been considered as one of their common pathogenic mechanisms. Cys–X–Cys ligand 9 (CXCL9) is an important factor to recruit effector neutrophils and lymphocytes in immunological reactions. However, the expression levels of CXCL9 in OSF and OLL remain unclear.

Materials and methods

We investigated the expression levels of CXCL9 in 10 normal buccal mucosa (NBM) samples and 56 OSF concomitant with OLL patients, and evaluated the possible mechanism of CXCL9 on their pathogenesis.

Results

Our results showed NBM demonstrated negative CXCL9 expression. OSF stained positive CXCL9 mainly in the cytoplasm of inflammatory cells and endothelial cells throughout the superficial layer of connective tissue, while its concomitant OLL showed much stronger CXCL9 in all mononuclear cells of subepithelial inflammatory infiltration (p = 0.0006). There was an upregulated trend of CXCL9 expression from NBM to OSF to OLL. However, no significant association between CXCL9 expression and clinicopathologic parameters of patients was found.

Conclusions

In conclusion, CXCL9 was found for the first time to contribute to the immunological pathogenesis for both OSF and its concomitant OLL, indicating a continuously enhanced intensity of immunoreactivity in their pathogenic process.

Clinical relevance

CXCL9 might be a useful tool to monitor the phase and disease severity of OSF and OLL, and a potential target for further clinical therapy for both lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pindborg JJ, Sirsat SM (1966) Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 22:764–779

    Article  PubMed  Google Scholar 

  2. Pindorg JJ (1989) Oral submucous fibrosis: a review. Annals Acad Med Singap 18:603–607

    Google Scholar 

  3. Reichart PA, Philipsen HP (2005) Betel and Miang. Vanishing Thai habits, 2nd edn. White Lotus Ltd. Co, Bangkok

    Google Scholar 

  4. Auluck A, Rosin MP, Zhang L, Sumanth KN (2008) Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature. J Can Dent Assoc 74:735–740

    PubMed  Google Scholar 

  5. Rajalalitha P, Vali S (2005) Molecular pathogenesis of oral submucous fibrosis—a collagen metabolic disorder. J Oral Pathol Med 34:321–328

    Article  PubMed  Google Scholar 

  6. Isaac U, Issac JS, Ahmed KN (2008) Histopathologic features of oral submucous fibrosis: a study of 35 biopsy specimens. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:556–560

    Article  PubMed  Google Scholar 

  7. Pindborg JJ, Mehat FS (1970) Occurrence of epithelial atypia in 51 Indian villagers with oral submucous fibrosis. Br J Cancer 24:253–257

    Article  PubMed  Google Scholar 

  8. Acay RR, Felizzola CR, de Araújo N, de Sousa SO (2006) Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol 42:475–480

    Article  PubMed  Google Scholar 

  9. van der Meij EH, Mast H, van der Waal I (2007) The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol 43:742–748

    Article  PubMed  Google Scholar 

  10. Mega H, Jiang WW, Takagi M (2001) Immunohistochemical study of oral lichen planus associated with hepatitis C virus infection, oral lichenoid contact sensitivity reaction and idiopathic oral lichen planus. Oral Dis 7:296–305

    Article  PubMed  Google Scholar 

  11. Chiang CP, Hsieh RP, Chen TH, Chang YE, Liu BY, Wang JT (2002) High incidence of autoantibodies in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med 31:402–409

    Article  PubMed  Google Scholar 

  12. Aggarwal BB (2004) Nuclear factor-kappa B: the enemy within. Cancer Cell 6:203–208

    Article  PubMed  Google Scholar 

  13. Laing KJ, Secombes CJ (2004) Chemokines. Dev Comp Immunol 28:443–460

    Article  PubMed  Google Scholar 

  14. Mantovani A (2005) Cancer: inflammation by remote control. Nature 435:752–753

    Article  PubMed  Google Scholar 

  15. Sallusto F, Mackay CR, Lanzavecchia A (2000) The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 18:593–520

    Article  PubMed  Google Scholar 

  16. Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106–115

    Article  PubMed  Google Scholar 

  17. Venetz D, Ponzoni M, Schiraldi M, Ferreri AJ, Bertoni F, Doglioni C (2010) Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer 127:2300–2312

    Article  PubMed  Google Scholar 

  18. Ichimura M, Hiratsuka K, Ogura N, Utsunomiya T, Sakamaki H, Kondoh T (2006) Expression profile of chemokines and chemokine receptors in epithelial cell layers of oral lichen planus. J Oral Pathol Med 35:167–174

    Article  PubMed  Google Scholar 

  19. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R (2001) Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194:398–405

    Article  PubMed  Google Scholar 

  20. Ning L, Xinchun J, Yanjia H, Chunjiao X, Yaozhi G, Xiaohuan Z (2008) Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis. CEBP 17:2249–2259

    Google Scholar 

  21. van der Meij EH, van der Waal I (2003) Lack of clinicopathological correlation in the diagnosis of oral lichen planus based on the presently available criteria and suggestions for modifications. J Oral Pathol Med 32:507–512

    Article  PubMed  Google Scholar 

  22. Juneja M, Mahajan S, Rao NN, George T, Boaz K (2006) Histochemical analysis of pathological alterations in oral lichen planus and oral lichenoid lesions. J Oral Sci 48:185–193

    Article  PubMed  Google Scholar 

  23. Ghalayani P, Razavi SM, Gholami D (2009) Comparative study of number and distribution of IgG cells in oral lichen planus and oral lichenoid lesions. Dent Res J 6:1–5

    Google Scholar 

  24. Chen HM, Hsieh RP, Yang H, Kuo YS, Kuo MY, Chiang CP (2004) HLA typing in Taiwanese patients with oral submucous fibrosis. J Oral Pathol Med 33:191–199

    Article  PubMed  Google Scholar 

  25. Tilakaratne WM, Klinikowski MF, Takashi S, Peters TJ, Saman W (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568

    Article  PubMed  Google Scholar 

  26. Gao ML, Tang JQ, Zhu ZT, Jian XF (1990) A pathological study of oral submucous fibrosis. Chin J Stomatol 25:363–365 [in Chinese]

    Google Scholar 

  27. Agarwal R, Saraswat A (2002) Oral lichen planus: an update. Drugs Today 38:533–547

    Article  PubMed  Google Scholar 

  28. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621

    Article  PubMed  Google Scholar 

  29. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Bröcker EB, Gillitzer R (1998) The CXC chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 183:89–95

    Article  Google Scholar 

  30. Liu L, Huang D, Matsui M, He TT, Hu T, Demartino J (2006) Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/-mice with experimental autoimmune encephalomyelitis. J Immunol 176:4399–4402

    PubMed  Google Scholar 

  31. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P (2007) Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492–520

    Article  PubMed  Google Scholar 

  32. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P (2011) Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Met 6:2010–2905

    Google Scholar 

  33. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J (1995) The functional role of the ELR motif in CXC chemokine mediated angiogenesis. J Biol Chem 270:27348–27357

    Article  PubMed  Google Scholar 

  34. Hogaboam CM, Steinhauser ML, Chensue SW, Kunkel SL (1998) Novel roles for chemokines and fibroblasts in interstitial fibrosis. Kidney 54:2152–2159

    Article  Google Scholar 

  35. Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK, Impens AJ (2011) Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 13:18

    Article  Google Scholar 

  36. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT (2008) Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 113:3620–3830

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Sciences Foundation of China (grant no. 81000445) and Foundation of Department of Science & Technology of Hunan Province in China (grant no. 2010TD2023).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Xiangya Road, Changsha, People’s Republic of China

    Ning Li, Canhua Jiang, Feng Guo, Xinchun Jian, Yanjia Hu & Zhangui Tang

  2. Department of Pain Management, The Second People’s Hospital, Furong Road, Changsha, People’s Republic of China

    Qiong Hu

  3. Department of Plastic Surgery, Victoria Hospital, Candos, Mauritius

    Krishna Munnee

Authors
  1. Ning Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Canhua Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Krishna Munnee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xinchun Jian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yanjia Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhangui Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ning Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, N., Hu, Q., Jiang, C. et al. Cys–X–Cys ligand 9 might be an immunological factor in the pathogenesis of oral submucous fibrosis and its concomitant oral lichenoid lesion. Clin Oral Invest 17, 1251–1258 (2013). https://doi.org/10.1007/s00784-012-0799-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00784-012-0799-9

Keywords

Search

Navigation